Stereotaxis Reports 2024 Third Quarter Financial Results

Rhea-AI Summary

Stereotaxis (NYSE: STXS) reported Q3 2024 financial results with total revenue of $9.2 million, up 18% year-over-year. System revenue was $4.4 million and recurring revenue was $4.8 million. The company achieved CE Mark for GenesisX robotic system and expects European CE Mark approval for MAGiC ablation catheter soon. Gross margin was 45%, with operating loss of $6.3 million. The quarter saw partial revenue recognition of three Genesis systems and orders for two additional systems. Cash balance stood at $11.0 million as of September 30, 2024, increasing to $13.3 million by end of October, with no debt.

Positive

• Revenue growth of 18% year-over-year to $9.2 million
• System revenue increased to $4.4 million from $3.5 million year-over-year
• Secured CE Mark approval for GenesisX robotic system
• Strong system backlog of over $15 million
• Healthy cash position of $13.3 million with no debt

Negative

• Operating loss increased to $6.3 million from $5.6 million year-over-year
• Net loss increased to $6.2 million from $5.4 million year-over-year
• Negative free cash flow of $4.2 million in Q3
• Gross margin impacted by higher proportion of system revenue

Insights

Financial Analyst

The Q3 results show mixed signals with both positive and concerning elements. Revenue growth of 18% year-over-year to $9.2 million demonstrates commercial progress, driven by Genesis system sales. The $15 million system backlog provides good revenue visibility. However, the widening operating loss of $6.3 million and significant cash burn remain challenges.

The balance sheet position with $13.3 million cash (post-October receipts) and no debt provides near-term stability but will require careful management given the quarterly cash burn rate of $4.2 million. The gross margin compression to 45% due to product mix and acquisition impacts needs monitoring. The APT acquisition appears strategically sound but integration costs are impacting near-term metrics.

Medical Research Analyst

The regulatory progress across multiple fronts signals significant potential for market expansion. Key developments include:

• Pending CE Mark for MAGiC ablation catheter
• Positive FDA engagement on MAGiC PMA submission
• CE Mark achievement for GenesisX system
• Advanced development of robotic high-density mapping and vascular guidance catheters
• Successful NMPA audit suggesting upcoming China market access

This comprehensive product ecosystem development could transform Stereotaxis' competitive position in endovascular robotics, particularly as they expand beyond cardiac applications.

ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2024.

“The past quarter was marked by solid commercial execution, continued broad-based technological progress, successful operational integration of APT, and maintained financial discipline,” said David Fischel, Chairman and CEO. “We are making broad, methodical progress in establishing the healthy foundations for a preeminent robotic surgery company.”

“Revenue growth in the third quarter was driven by continued demand for Genesis with partial revenue recognition of three robotic systems. We received orders for two Genesis systems during the third quarter and expect to receive the first GenesisX order in the near future. A robust system pipeline along with existing system backlog of over $15 million supports continued revenue growth.”

“We are driving broad-based progress across the late stages of a comprehensive innovation strategy. European CE Mark approval of the MAGiC ablation catheter is expected in the near future. Engagement with the FDA on the MAGiC PMA submission has continued to advance well. We attained CE Mark for the GenesisX robotic system in the third quarter and the FDA provided its first round of questions on the US submission. Following our recent acquisition of APT, we completed manufacturing of hundreds of catheters needed for formal regulatory testing of the first ever robotic high-density mapping catheter and vascular guidance catheter, both of which are expected to be submitted for regulatory approvals next quarter. A recent audit by the Chinese NMPA regulatory body was completed successfully, portending well for near term approvals in China. This broad-based progress on a new foundational product ecosystem is transformational clinically, commercially and strategically as we make robotics increasingly impactful and accessible across endovascular surgery.”

“The acquisition of APT in the third quarter is already demonstrating commercial and strategic value. I want to thank and highlight both teams for the significant efforts and accomplishments in integrating operations successfully. The unique expertise of APT is highly complementary and additive to Stereotaxis’ strategy as we increasingly focus on a broad family of robotically-steered endovascular devices.”

“We remain cognizant of the importance of maintaining financial strength and discipline. Increased system revenue late in the third quarter led to significant associated cash receipts, providing us a solid balance sheet with over $13 million in cash and no debt at the end of October.”

2024 Third Quarter Financial Results
Revenue for the third quarter of 2024 totaled $9.2 million, an 18% year-over-year increase compared to $7.8 million in the prior year third quarter. System revenue for the quarter was $4.4 million and recurring revenue was $4.8 million, compared to $3.5 million and $4.3 million in the prior year third quarter, respectively. System revenue growth reflects revenue recognition on the partial delivery of three Genesis systems. Recurring revenue growth benefited from a partial quarter contribution from the previously announced acquisition of Access Point Technologies.

Gross margin for the third quarter of 2024 was 45% of revenue. Gross margin was impacted by the higher proportion of system revenue and by acquisition-related accounting that temporarily reduces disposable margin. Operating expenses in the third quarter of $10.4 million include $2.5 million in non-cash stock compensation expense and a $0.7 million non-cash, mark-to-market adjustment for acquisition related contingent earnout consideration. Excluding these non-cash charges, adjusted operating expenses in the quarter were $7.2 million, compared to $7.1 million in the prior year third quarter. Operating expenses in the third quarter include the partial quarter operating expenses of Access Point Technologies.

Operating loss and net loss in the third quarter were ($6.3) million and ($6.2) million, respectively, compared with ($5.6) million and ($5.4) million in the prior year third quarter. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense and the mark-to-market adjustment, were ($3.1) million and ($3.0) million, respectively, compared with ($3.0) million and ($2.8) million in the previous year. Negative free cash flow for the third quarter was ($4.2) million.

Cash Balance and Liquidity
At September 30, 2024, Stereotaxis had cash and cash equivalents, including restricted cash, of $11.0 million and no debt. Significant cash receipts in October increased Stereotaxis’ balance of cash and cash equivalents, including restricted cash, to $13.3 million at the end of October.

Forward Looking Expectations
Stereotaxis reiterates its expectation for full year revenue to be approximately equal to the previous year, and expects continued year-over-year revenue growth in both system and recurring revenue in the upcoming quarters.

Stereotaxis anticipates ending the year with approximately $12 million cash and no debt. It expects this balance sheet to allow it to advance its transformative product ecosystem to market, fund its commercialization, and reach profitability without the need for additional financing.

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, November 11, 2024, at 4:30 p.m. Eastern Time. To access the conference call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 7792742. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

STEREOTAXIS, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except share and per share amounts)	Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Revenue:
Systems	$	4,391			$	3,539			$	7,243			$	8,673
Disposables, service and accessories		4,805				4,260				13,335				13,533
Total revenue		9,196				7,799				20,578				22,206
Cost of revenue:
Systems		3,673				2,909				5,760				7,309
Disposables, service and accessories		1,424				831				3,440				2,775
Total cost of revenue		5,097				3,740				9,200				10,084
Gross margin		4,099				4,059				11,378				12,122
Operating expenses:
Research and development		2,454				2,668				6,970				8,061
Sales and marketing		3,152				3,097				9,456				9,585
General and administrative		4,838				3,933				12,064				11,011
Total operating expenses		10,444				9,698				28,490				28,657
Operating loss		(6,345	)			(5,639	)			(17,112	)			(16,535	)
Other income		5				-				2				27
Interest income, net		150				270				580				835
Net loss	$	(6,190	)		$	(5,369	)		$	(16,530	)		$	(15,673	)
Cumulative dividend on convertible preferred stock		(328	)			(338	)			(984	)			(1,004	)
Net loss attributable to common stockholders	$	(6,518	)		$	(5,707	)		$	(17,514	)		$	(16,677	)
Net loss per share attributed to common stockholders:
Basic	$	(0.08	)		$	(0.07	)		$	(0.21	)		$	(0.21	)
Diluted	$	(0.08	)		$	(0.07	)		$	(0.21	)		$	(0.21	)
Weighted average number of common shares and equivalents:
Basic		85,824,789				82,468,971				84,629,531				80,028,243
Diluted		85,824,789				82,468,971				84,629,531				80,028,243

STEREOTAXIS, INC. BALANCE SHEETS
(in thousands, except share amounts)	September 30, 2024				December 31, 2023
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	10,663			$	19,818
Restricted cash - current		350				525
Accounts receivable, net of allowance of $661 and $672 at 2024 and 2023, respectively		7,921				3,822
Inventories, net		9,009				8,426
Prepaid expenses and other current assets		869				676
Total current assets		28,812				33,267
Property and equipment, net		3,733				3,304
Goodwill		4,494				-
Intangible assets		8,162				-
Restricted cash		-				219
Operating lease right-of-use assets		5,618				4,982
Prepaid and other non-current assets		116				137
Total assets	$	50,935			$	41,909
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	6,403			$	3,190
Accrued liabilities		3,376				2,972
Deferred revenue		5,092				6,657
Current contingent consideration		5,298				-
Current portion of operating lease liabilities		552				428
Total current liabilities		20,721				13,247
Long-term deferred revenue		2,102				1,637
Long-term contingent consideration		6,251				-
Operating lease liabilities		5,583				5,062
Other liabilities		55				43
Total liabilities		34,712				19,989
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized, 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively		5,408				5,577
Stockholders' equity:
Common stock, par value $0.001; 300,000,000 shares authorized, 84,713,400 and 80,949,697 shares issued at 2024 and 2023, respectively		85				81
Additional paid-in capital		565,146				554,148
Treasury stock, 4,015 shares at 2024 and 2023		(206	)			(206	)
Accumulated deficit		(554,210	)			(537,680	)
Total stockholders' equity		10,815				16,343
Total liabilities and stockholders' equity	$	50,935			$	41,909

FAQ

What was Stereotaxis (STXS) revenue in Q3 2024?

Stereotaxis reported total revenue of $9.2 million in Q3 2024, representing an 18% increase from $7.8 million in Q3 2023.

How many Genesis systems did Stereotaxis (STXS) sell in Q3 2024?

Stereotaxis received orders for two Genesis systems during Q3 2024 and recognized partial revenue from three robotic systems.

What is Stereotaxis (STXS) current cash position?

As of October 2024, Stereotaxis had $13.3 million in cash and cash equivalents, including restricted cash, with no debt.

What regulatory approvals did Stereotaxis (STXS) receive in Q3 2024?

Stereotaxis received CE Mark approval for the GenesisX robotic system in Q3 2024.